ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
Revenue of ESSA Pharma Inc. (EPIX)
Revenue in 2023 (TTM): $
According to ESSA Pharma Inc.'s latest financial reports the company's current revenue (TTM) is $. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of ESSA Pharma Inc.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $ | $-118,491 | $-26,455,309 | $-26,580,743 | $-26,582,343 |
| 2022 | $ | $-121,787 | $-35,079,536 | $-35,215,000 | $-35,103,000 |
| 2021 | $ | $-109,464 | $-36,708,125 | $-36,839,810 | $-36,805,461 |
| 2020 | $ | $-110,324 | $-23,005,582 | $-23,734,000 | $-23,445,000 |
| 2019 | $ | $ | $-12,134,000 | $-10,403,000 | $-10,441,000 |
| 2018 | $ | $-34,488 | $-10,767,518 | $-11,603,000 | $-11,630,000 |
| 2017 | $ | $-46,145 | $-3,551,895 | $-4,383,000 | $-4,499,000 |
| 2016 | $217 | $-65,964 | $-18,665,880 | $-12,989,000 | $-13,140,000 |
| 2015 | $ | $ | $-9,376,561 | $-8,568,167 | $-8,568,167 |
| 2014 | $ | $ | $-1,755,786 | $-1,823,929 | $-1,823,929 |
| 2013 | $ | $ | $-1,338,197 | $-1,371,321 | $-1,371,321 |
| 2012 | $ | $ | $-1,914 | $-1,938 | $-1,938 |